Notice of Proposed Sale · 144
Avalo Therapeutics, Inc.
AVTXNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- AVALO THERAPEUTICS, INC.
- Issuer CIK
- 0001534120
- SEC file number
- 001-37590
- Phone
- 4105228707
- Person for whose account securities are to be sold
- CHRISTOPHER RYAN SULLIVAN
- Relationships to issuer
- Officer
- Street
- 1500 Liberty Ridge Drive, Suite 321
- City
- Wayne
- State / country code
- PA
- Postal code
- 19087
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 70,709 | 1,385,189.31 | 53,629,989 | 08/17/2026 | NASDAQ | Morgan Stanley Smith Barney LLC Executive Financial Services |
Broker / market maker — proposed row 1, entry 1
- Name
- Morgan Stanley Smith Barney LLC Executive Financial Services
- Street
- 1 New York Plaza
- Street (continued)
- 8th Floor
- City
- New York
- State / country code
- NY
- Postal code
- 10004
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 08/17/2026 | Exercise of Stock Options | Issuer | 70,709 | N | 08/17/2026 | Cash |
Prior-sale reporting
- Nothing to report for the preceding three months
- Y
Remarks
The securities to be sold were and will be received upon the exercise of stock options over the next three months. The dates of acquisition and payment were and will be the dates of exercise/sale.
Notice signature
- Notice date
- 08/17/2026
- Signed
- /s/ Christopher Ryan Sullivan
- Plan adoption dates
- 05/18/2026
Company context
Current securities
Recent company filings
- SCHEDULE 13G/A - filed by FMR LLC regarding Avalo Therapeutics, Inc.Nov 6, 2026
- SCHEDULE 13G/A - filed by FMR LLC regarding Avalo Therapeutics, Inc.Nov 5, 2026
- Entry into a Material Definitive Agreement · Termination of a Material Definitive AgreementNov 5, 2026
- S-3ASR filingNov 5, 2026
- 424B5 filingNov 5, 2026